Oncology
Showing all 8 results
-
Acute Myeloid Leukemia (AML) -The Changing Landscape of Treatment in AML, Executive Deck 2020
$7,500.00 – $12,500.00Select optionsAcute myelogenous leukemia (AML) Disease Landscape provides comprehensive market intelligence with epidemiology, keen insight into current treatment paradigms, in-depth pipeline coverage ( ~ 470 unique industry-sponsored studies) and clinical trial landscape supported by detailed recent results (~ 96 trial’s results) from ASH 2019, ASCO 2020 and EHA 2020. The drugs are further classified according to the class of therapies: antibody drug conjugates, bispecific antibodies, tri-specific and monoclonal antibodies, CAR-T therapies & T cells therapies, vaccines, small molecules and others.
-
Acute Myeloid Leukemia (AML) -The Changing Landscape of Treatment in AML, Executive Deck 2020
$7,500.00 – $15,450.00Select optionsAcute myelogenous leukemia (AML) Disease Landscape provides comprehensive market intelligence with epidemiology, keen insight into current treatment paradigms, in-depth pipeline coverage ( ~ 470 unique industry-sponsored studies) and clinical trial landscape supported by detailed recent results (~ 96 trial’s results) from ASH 2019, ASCO 2020 and EHA 2020. The drugs are further classified according to the class of therapies: antibody drug conjugates, bispecific antibodies, tri-specific and monoclonal antibodies, CAR-T therapies & T cells therapies, vaccines, small molecules and others.
-
Adult Acute Lymphoblastic Leukemia (aALL) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030
$6,500.00 – $19,500.00Select optionsAbout 60% of ALL adult patients relapse or are refractory to first-line therapy and a high unmet need continues to exist. CD19 CAR T candidate with compelling activity and safety profile and has the potential to change the standard of care as a curative therapy for r / r ALL. Sales of emerging therapies to treat adult Acute Lymphoblastic Leukemia (aALL) in the countries under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2020-2030 study period, adding an estimated value to a total $1.2 billion market by 2030.
-
Adult Acute Lymphoblastic Leukemia (aALL) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030
$9,750.00 – $19,500.00Select optionsAbout 60% of ALL adult patients relapse or are refractory to first-line therapy and a high unmet need continues to exist. CD19 CAR T candidate with compelling activity and safety profile and has the potential to change the standard of care as a curative therapy for r / r ALL. Sales of emerging therapies to treat adult Acute Lymphoblastic Leukemia (aALL) in the countries under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2020-2030 study period, adding an estimated value to a total $1.2 billion market by 2030.
-
Sale!
Chimeric Antigen Receptor (CAR-T) Cell Therapy – Market Opportunity, Pipeline & Competitive Intelligence 2020
$2,400.00 – $7,200.00Select optionsChimeric antigen receptor (CAR) T-cell therapy has generated a great amount of interest and have encouraged investors to support development in the field of adoptive cellular immunotherapy. Over the past couple of years, there has been rapid progress in the field. Researchers are refining the safety and efficacy profiles of CAR T cells with new concepts and technologies. These will be therapies that will address current challenges through mechanisms of superior efficacy, safety and delivery. -
Neuroblastoma | Landscape & Forecast | Competitive Landscape & Forecast, 2020-2030
$5,250.00 – $15,750.00Select optionsThe Neuroblastoma report provides the detailed overview of the disease and exhaustive understanding of historical and forecasted epidemiology. It highlights the prevailing treatment patterns, potential upcoming drugs and also identifies better of the market opportunities by providing the historical and forecasted market revenue, sales trends, and drug uptake during the study period from 2019-2030.
-
T-Cell Receptor (TCR) Therapy- Executive Report 2020
$3,000.00 – $9,000.00Select optionsA Comprehensive Review on TCR Cell Therapy by Pipeline Analysis, Emerging Players having Innovative Portfolio, Commercial Assessment of Developmental Activities, Therapeutic Portfolio Assessment, Objective Assessment of Unmet Needs, Future Perspectives, and Technological Advancements to make informed R&D related decisions, modify therapeutic portfolio strategies, identify growth opportunities, strengthen or expand business by gaining extensive view.
-
TIGIT Inhibitors – Market Opportunity, Pipeline & Competitive Intelligence 2020
$3,950.00 – $11,850.00Select optionsThis TIGIT report covers the TIGIT market opportunity providing Key Competitive Analysis, 15+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc), Licensing and Agreements, Business Agreement, business partner, Clinical Agreement, 2020 Earnings call update, Market launch preparation, Marketing Strategy, Future agenda and Upcoming events.